Premium
Pharmacodynamic Modeling of Finasteride, a 5α‐Reductase Inhibitor
Author(s) -
Ko Hui C.,
Jusko William J.
Publication year - 1995
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1995.tb04389.x
Subject(s) - finasteride , pharmacodynamics , dihydrotestosterone , medicine , testosterone (patch) , pharmacology , 5 alpha reductase inhibitor , pharmacokinetics , endocrinology , androgen , prostate , cancer , hormone
Finasteride is a 4‐azasteroid inhibitor of one isoenzyme of 5α‐reductases that converts testosterone to dihydrotestosterone (DHT). We characterized the time course of DHT concentrations. The following model was used to assess DHT pharmacodynamics: where joint fitting of three dose levels yielded k o in = 28% change/hour, k out = 0.28 hour 1 , IC 50 = 0.012 ng/ml, and E max = 0.7. The modification of a previous model with the maximum partial effect factor, E max , may be useful in characterizing the pharmacodynamics of drugs with similar indirect mechanisms.